Mallinckrodt partners on NSAID
June 18th, 2009
Covidien Ltd.’s Mallinckrodt Inc. unit based in Hazelwood and Nuvo Research Inc. of Canada have agreed to collaborate on developing two topical formulations of diclofenac, a non-steroidal anti-inflammatory drug used to treat pain. Covidien said Tuesday that the agreement is aimed at expanding its entry into the branded pain management market. One of the products, Pennsaid, is awaiting Food and Drug Administration approval and the second formulation, Pennsaid Plus, is in development freecreditscore. Nuvo will make the products in Varennes, Quebec, and Covidien will be responsible for marketing, selling and medical education. (Gail Appleson)
Filed under: marketing by Guru